Research Programs: Cancer Outcomes and Survivorship, Prevention & Etiology
Assistant Professor, Division of Epidemiology and Community Health, School of Public Health

robie004@umn.edu
612-625-8279, office

Research Interests

Use of molecular epidemiologic and pharmacogenetic approaches to investigate the impact and gene-environment interactions on various outcomes related to cancer treatment and recovery.

Selected Publications

Robien K, Ulrich CM, Bigler J, Yasui Y, Gooley T, Bruemmer B, Potter JD, Radich JP. Methylenetetrahydrofolate reductase genotype affects risk of relapse following hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res 2004; 10(22): 7592-7598. PMID: 15569990

Robien K, Boynton A, Ulrich CM. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 2005; 6(7): 673-689. PMID: 16207145

Robien K, Schubert MM, Yasui Y, Martin P, Storb R, Potter JD, Ulrich CM. Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-vs-host disease or relapse following hematopoietic transplantation. Bone Marrow Transplantation 2006; 37(7):687-692. PMID: 16501595

Robien K, Bigler J, Yasui Y, Potter JD, Martin P, Storb R, Ulrich CM. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute-graft-vs-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biology of Blood and Marrow Transplantation 2006; 12(9): 973-980. PMID: 16920564

Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. Cancer Causes Control 2007; 18(7):775-782. PMID: 17549593